Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • NielQC
    Junior Member
    • Nov 2016
    • 2

    #1

    Panel Validation using NA12878 DNA

    Hi there,

    we have made a panel that comprises several (190) exonic alterations and now we want to test how capable are we to call these variants starting from a DNA sample. This post is for retrieve suggestions about how can we do this and/or to know if my approach is not correct.

    Basically what I have been thinking about is purchasing NA12878 DNA from Coriell Institute, sequencing it and running a variant calling pipeline (without going into details, mapping vs GRCh37 and call variants with mpileup). Once I have the variants, check them vs the high-confidence calls set focusing on my 190 exonic alterations and if the alleles matches at these positions would mean that we call these variants correctly.

    Is this a correct way?

    Previously, aiming to evaluate just the bioinformatic pipeline and not the laboratory part, I did the same analysis with the GIAB NA12878 dataset (HiSeq x300) and checked the output variants with this callset ftp://ftp.ncbi.nlm.nih.gov/giab/ftp/...ransfer.vcf.gz available at the GIAB ftp site. Previously I normalized the variants representation of both calls sets using *vcflib vcfallelicprimitives*.

    And a last question. For my validation purpose, is there any difference between purchasing the NIST reference DNA and purchasing the Coriell Institute DNA Sample? I think it's the same, but look the difference in prices...

    Any suggestion will be welcome
    Last edited by NielQC; 05-05-2017, 04:00 AM.

Latest Articles

Collapse

  • SEQadmin2
    Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
    by SEQadmin2



    CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

    Despite this, “CRISPR helped turn genome editing from a specialized technique into
    ...
    07-31-2026, 11:01 AM
  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    07-20-2026, 11:48 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, Today, 12:22 PM
0 responses
12 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 08-11-2026, 10:35 AM
0 responses
13 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 08-06-2026, 07:41 AM
0 responses
30 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 08-03-2026, 10:13 AM
0 responses
48 views
0 reactions
Last Post SEQadmin2  
Working...